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Neutrophil to lymphocyte ratio 
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on efficacy of immune checkpoint 
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Steroids are often utilized to manage patients with non‑small cell lung cancer brain metastases 
(NSCLCBM). Steroids and elevated neutrophil‑to‑lymphocyte ratio (NLR) have been associated 
with decreased overall survival (OS) in patients treated with immune checkpoint inhibitors (ICI). We 
retrospectively investigated patients treated with ICI after the diagnosis of NSCLCBM at a single 
tertiary care institution examing the impact of steroids and NLR. Overall survival (OS) and intracranial 
progression‑free survival (PFS) were analyzed. 171 patients treated with ICI for NSCLCBM were 
included. Thirty‑six received steroids within 30 days of the start of ICI, and 53 patients had an NLR ≥ 5 
before the start of ICI. Upfront steroids was associated with decreased OS on multivariable analysis 
(median OS 10.5 vs. 17.9 months, p = .03) and intracranial PFS (5.0 vs. 8.7 months, p = .045). NLR ≥ 5 
was indicative of worse OS (10.5 vs. 18.4 months, p = .04) but not intracranial PFS (7.2 vs. 7.7 months, 
p = .61). When NLR and upfront steroids are modeled together, there is a strong interaction (p = .0008) 
indicating that the impact of steroids depended on the patient’s NLR. In a subgroup analysis, only 
in patients with NLR < 4 was there a significant difference in OS with upfront steroids (26.1 vs. 
15.6 months, p = .032). The impact of steroids on the efficacy of ICI in patients with NSCLCBM is 
dependent on the patient’s NLR underscoring its importance in these patients. Patients with a low 
NLR, steroid use decreases the efficacy of ICI. These results can inform clinicians about the impact of 
steroids in patients treated with ICI.
Abbreviations
NSCLCBM  Non-small cell lung cancer brain metastases
ICI  Immune checkpoint inhibitors
BM  Brain metastases
NLR  Neutrophil to lymphocyte ratio
WBRT  Whole-brain radiation therapy
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SRS  Stereotactic radiosurgery
OS  Overall survival
PFS  Progression-free survival
KPS  Karnofsky performance status
PD-L1  Programmed death ligand-1
EGFR  Epidermal growth factor receptor
ALK  Anaplastic lymphoma receptor tyrosine kinase
KRAS  V-Ki-Ras2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog
Approximately 10–30 percent of patients with Non-Small Cell Lung Cancer (NSCLC) will develop brain metas-
tases (BM) during the course of their  disease1,2. Historically, systemic chemotherapies have shown minimal 
intracranial  efficacy3–5. However, the development of targeted and immune-modulating therapies have changed 
treatment paradigms in NSCLCBM. In patients without targetable driver mutations, immune checkpoint inhibi-
tors (ICIs) are commonly-used systemic therapeutic options for managing intracranial  metastases6,7. While early 
trials provided some evidence for intracranial  efficacy8–10, the wide-scale use of ICI in patients with NSCLC has 
provided an opportunity for retrospective  investigation11.
As a result of the widespread use of ICI in patients with NSCLCBM, there is a growing interest in identifying 
factors predictive of therapeutic response in this patient population. Steroids are frequently used for symptomatic 
management of patients with NSCLCBM to treat fatigue, dyspnea, decreased appetite, and other cancer-related 
symptoms, however, their immune-supressive mechanism of action is hypothesized to antagonize ICI activity. 
The first evidence of this was reported in a phase 2 clinical trial in melanoma BM, which demonstrated a better 
response to ICI in patients who did not receive upfront steroids and were neurologically asymptomatic when 
compared to patients who received  steroids12. Since then, studies have shown that the use of steroids within the 
first 30 days of initiating ICI is associated with a decrease in  OS13,14. However, others have argued that this associa-
tion exists only because the patients with a worse prognosis are more likely to receive  steroids15. There is a paucity 
of literature showing direct correlation between steroid use and outcome in patients receiving ICI for NSCLCBM.
Another clinical marker, neutrophil to lymphocyte ratio (NLR), has been proposed as a surrogate for immune 
 activity16–20. Multiple studies in NSCLC have reported an elevated NLR at the start of immunotherapy is associ-
ated with a poor  prognosis21–24. However, there is limited data investigating the impact of NLR in patients with 
BM and its interaction with steroid use.
In this study, we investigated the impact of upfront steroids and NLR on OS and PFS in a cohort of patients 
who began ICI after the diagnosis of NSCLCBM, a patient cohort with a universaly poor prognosis. We hypoth-
esized that even within this group, upfront steroid use and elevated NLR would result in a decrease in OS and 
intracranial PFS.
Methods
Patient selection and treatment. This IRB-approved retrospective cohort study included consecutive 
NSCLCBM patients treated with ICI with the diagnosis of BM from 2015 to 2019 at a single tertiary-care institu-
tion. Patient information was gathered retrospectively from charts and therefore the IRB waived the informed 
consent requirement. Patient characteristics, diagnostic information, and treatment details were abstracted from 
the shared electronic medical record. This included Karnofsky Performance Score (KPS), number of BMs, pres-
ence of extra-cranial metastases, neurologic symptoms, age, PD-L1 status in the primary tumor, and molecular 
markers (EGFR, ALK, PDL1, KRAS). Treatment details included the number of cycles of ICI and local intracra-
nial treatment such as whole brain radioation therapy (WBRT), surgery, and stereotactic radiosurgery (SRS) at 
any time after diagnosis of BM.
All patients who were > 18 years of age with pathologically confirmed diagnosis of NSCLC and treated with 
one or more of the ICIs (nivolumab, pembrolizumab, atezolizumab, or ipilimumab) were included in our study. 
Patients were followed in the clinic with surveillance MRIs every 2–3 months. Intracranial progression was 
defined utilizing a modified iRANO brain metastases  criteria25,26. Progression was defined as a greater than 20% 
increase in the sum of the longest diameter of target lesions, the unequivocal progression of enhancing non-
target lesions, new lesions, or death. For cases of potential pseudoprogression, the judgement of the hospitals 
interdisciplinary tumor board was utilized. All patients who received ICI before their diagnosis of BM were 
excluded from our study.
Steroid and NLR data. Upfront steroid use was defined as any outpatient prescription of steroids within 
the first 30 days of the beginning of immunotherapy. NLR was calculated from the complete blood count (CBC) 
on the day of the start of ICI or the most recent CBC with differential data within one month prior to the start 
of ICI.
Statistical analysis. For baseline characteristics, continuous data were compared across cohorts with 
Student’s t-test or Wilcoxon rank-sum test, while categorical data were compared with Chi-squared tests. The 
Kaplan–Meier method was used to estimate OS and PFS from the start of ICI. Patients were grouped accord-
ing to upfront steroid usage and NLR, with time-to-event differences tested according to the Wilcoxon test as 
we desired to give more weight to early events. Multivariable analysis for OS and PFS was conducted utilizing 
Cox-proportional hazards models. Models were adjusted for the following covariates: age at diagnosis of BM, 
presence of extracranial metastases, number of BM, KPS, and the presence of neurological symptoms at diag-
nosis of BM. Covariates were chosen based upon previously described risk factors for local failure and variables 
prognostic for survival. Multicollinearity was assessed by examining the variance inflation factors. In addition 
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to the main effects model, NLR was allowed to modify the effect of steroid usage with the inclusion of a cross-
product term.
Test for covariate interaction between NLR and steroid use was performed. NLR was treated as both a continu-
ous variable in some analysis and as a dichotomous variable with a cut-off between 4–6 in others, as reported in 
previous  studies14,24. In order to determine the individual contributions of both the neutrophil and lymphocyte 
counts, patients were grouped according to a neutrophil count cut-off of 8000 (cells/mm3) or lymphocyte count 
of 1000 (cell/mm3) and compared with respect to OS and PFS. Similar comparisons were conducted after keep-
ing both variables  continuous27.
Statistical significance was defined as a p-value of less than 0.05. JMP Pro version 14 statistical software (SAS 
Institute, Cary, NC) was utilized for analysis. GraphPad Prism 8 (San Diego, California) was utilized for the 
generation of images.
Ethics approval. This retrospective chart review study involving human participants was in accordance 
with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Dec-
laration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) 
of the Cleveland Clinic approved this study (Protocol #09-911).
Results
Patient characteristics. Within the study period, 171 patients were treated with ICI after the diagnosis 
of NSCLCBM. The ICI received included nivolumab (n = 101), pembrolizumab (n = 52), atezolizumab (n = 14), 
durvalumab (n = 3) and ipilimumab (n = 1). Within our cohort, the grade prognostic assessment (GPA) remains 
a strong predictor of OS as patients with a GPA of 2 or greater had a better prognosis than patients with a GPA of 
less than 2 (median survival 21 vs 13.4 months, p = 0.03). Thirty-six patients were treated with upfront steroids 
with a median duration of 2 months (range 0.1–12) and a median prednisone equivalent dose of 27 mg per day 
(range 5–107), with 29 of these patients receiving dexamethasone. Patient demographics and covariates that are 
known to be prognostic of OS in NSCLCBM are documented in Table 1. There was no significant difference in 
these variables between the upfront steroids group and the control group. More patients who received upfront 
steroids had neurologic symptoms at the diagnosis of BM, but this was only marginally significant (68.6% vs. 
51.9%, p = 0.08). After splitting the cohort by NLR status, we observed that patients with an NLR ≥ 5 were more 
likely to be male patients (p = 0.006). Additionally, patients with NLR < 5 were more likely to have undergone sur-
gical resection of an intracranial lesion at any time after diagnosis of BM (p = 0.003). On univariate OS analysis 
of previously correlated variables, none of the variables showed statistical significance (Supplemental Table S1).
Impact of upfront steroids. The use of upfront steroids was marginally associated with a lower median 
OS (10.5 months) compared to patients who did not receive upfront steroids (17.9 months) (unadjusted p = 0.06) 
(Fig. 1a). After adjustment, the use of upfront steroids (HR: 1.82, p = 0.03) and increasing age (HR: 1.03, p = 0.02) 
were significantly associated with reduced OS (Fig. 1b). In patients that received upfront steroids, the dose of 
steroids did not correlate with OS (HR = 0.99, p = 0.57). Additionally, we separated patients by the duration of 
received steroids into greater than or equal to 2 months compared to less than 2 months and found no associa-
tion (p = 0.23). The same held for dichotomization at 1 and 3 months (p = 0.69 and p = 0.46 respectively).
In terms of intracranial PFS, the use of upfront steroids led to a decrease in median PFS from 8.7 months 
to 5 months (p = 0.02) (Fig. 1c). After adjustment, the use of upfront steroids was significantly associated with 
decreased intracranial PFS (HR:1.66, p = 0.045) (Fig. 1d).
Impact of NLR. NLR data was available for 148 patients in our cohort (87%). NLR of ≥ 5 was indicative of 
worse OS (Fig. 2a). The median OS with an NLR of ≥ 5 was 10.5 months versus 18.4 months with an NLR < 5 
(unadjusted p = 0.002). After adjustment, NLR of ≥ 5 was significantly associated with decreased OS (HR:1.64, 
p = 0.04) (Fig.  2b). However, unlike upfront steroids, NLR was not predictive of intracranial PFS (p = 0.61) 
(Fig. 2c). After adjustment, there remained no evidence of an association among NLR and PFS. (Fig. 2d).
Due to the arbitrary nature of the NLR cut-off of 5, a cut-off of 4 and 6 were also explored. The NLR cut-off of 
4 demonstrated a significant association with OS (p < 0.001) and a non-significant association with PFS (p = 0.58). 
The NLR cut-off of 6 was also associated with significant OS (p < 0.0001) and a non-significant association with 
PFS (p = 0.17). When NLR was used as a continuous variable, NLR did not show a significant association with 
OS (HR = 1.03, p = 0.07), suggesting there may be a range of values where NLR does not impact OS after start of 
ICI (nonlinear association).
To determine the individual contribution of the neutrophil count, a cut-off of 8000 cell/mm3 was utilized. 
Patients with a neutrophil count over 8000 cell/mm3 had a significantly worse OS compared to those less than 
8000 cell/mm3 with a median survival of 7.2 months versus 18.7 months (p = 0.0001). Neutrophil count used as 
a continuous variable also led to a HR of 1.065 (95% CI: 1.02–1.10, p = 0.002). When investigating the impact 
of lymphocyte count utilizing a cut-off of 1000 cell/mm3, we found no evidence of a difference in OS (p = 0.40) 
or PFS (p = 0.13). Additionally, when lymphocyte count was used as a continuous variable, the HR for OS was 
0.91 (95% CI: 0.65–1.16, p = 0.52).
Impact of upfront steroids is dependent on NLR. In order to determine if the impact of steroids was 
dependent of NLR we created a multivariable model that included an interaction term between upfront steroid 
use and continuous NLR and found a strong significant interaction (p < 0.001) (Table 2). Utilizing this model, 
the HR for upfront steroid usage was calculated across NLR values ranging from 0.5 to 11 and graphed in Fig. 3a. 
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These results demonstrate that steroids have a large negative impact on survival in patients with a low NLR. 
However, steroids have a minimal and possibly beneficial effect on survival in patients with a high NLR.
We then separated our cohort into two groups based on an NLR of above or below 4, based on the value in 
Fig. 3a where the hazard ratio crosses 1. In patients with an NLR below 4, steroid use was significantly associ-
ated with decreased OS (26.1 vs. 15.6 months, p = 0.032) (Fig. 3b). This was confirmed on multivariable analysis 
(p = 0.02) (Supplemental Table S2a). Whereas, in patients with an NLR ≥ 4, steroids had no impact on OS (11.1 
vs. 10.5 months, p = 0.66) (Fig. 3c), and this held on multivariable analysis (HR = 0.79, p = 0.59) (Supplemental 
Table S2b).
Local therapy. The interaction between radiation therapy and ICI has been previously  documented11. In 
our cohort, 126 patients of 171 received only SRS, eight patient received only WBRT, 34 patients received WBRT 
and SRS and zero patients only underwent a craniotomy after the diagnosis of BM. Only six patients had a crani-
otomy after starting ICI. Impact of SRS versus no SRS was investigated but no significant findings were observed. 
Of interest, 17 patients received WBRT after of starting ICI and these patients had a far worse prognosis. When 
WBRT after start of ICI was added our models for overall survival, there was a significant hazard ratio ranging 
from 2.25–2.44. This did not alter any of the earlier conclusions (Supplemental Table S3).
Discussion
ICIs are the standard of care in NSCLC and have rapidly improved the outcomes of these patients. Since the 
start of ICI clinical trials, determining which patients will respond best to ICI has been a goal of clinicians and 
scientists. For example, reseachers have found that patients negative for the expression of the two most frequent 
HLA-A alleles a worse prognosis in NSCLC treated with  ICI28,29. Others have found that commonly utilized 
medications like systemic antibiotics and proton-pump inhibitors can decrease the efficacy of  ICIs30.
Table 1.  Patient characteristics. (A) Patients separated into cohorts based upon upfront steroid usage within 
30 days of start of immunotherapy. (B) Patients separated into cohorts based upon NLR status (≥ 5 vs. < 5). 
p-value: a. Student’s t-test, b. Pearson Chi-square test c. Wilcoxon sum test.
(A) No upfront steroids (n = 135) Upfront steroids (n = 36) p value
Age, mean (SD) 64 (9.5) 62 (9.2) .17a
% Male 44% 44% .94b
% Caucasian 86% 81% .42b
%PD-L1 Positive 79.6 92.3 .25b
% with Extracranial Metastases 50% 53% .80b
Baseline Number of Intracranial Lesions, mean (SD) 2.8 (3.4) 2.4 (1.6) .39a
KPS (median  (Q1–Q3)) 90 (80–90) 85 (70–90) .28c
% with Neurological Symptoms at Diagnosis 52% 69% .08b
Mean Number of SRS treatments (SD) 1.85 (1.31) 1.91 (1.20) .80a
% that received WBRT 24% 28% .61b
% Craniotomy 15% 17% .61b
% EGFR mutation 9% 10% .91b
% ALK rearrangement 2% 3% .56b
% KRAS mutation 49% 55% .62b
(B) NLR ≥ 5 (n = 53) NLR < 5 (n = 95) p value
Age, mean (SD) 65 (9.1) 63 (9.6) .21a
% Male 60% 37% .006b
% Caucasian 83% 86% .72b
%PD-L1 Positive 77.3 82.9 .59b
% with Extracranial metastases 57% 47% .19b
Baseline Number of Intracranial Lesions, mean (SD) 3.3 (4.2) 2.4 (2.4) .14a
KPS (median  (Q1–Q3)) 90 (80–90) 90 (80–90) .47c
% with Neurological Symptoms at Diagnosis 51% 56% .53b
Mean Number of SRS treatments (SD) 1.5 (1.0) 2.0 (1.3) .01a
% that received WBRT 28% 22% .40b
% Craniotomy 2% 20% .003b
% EGFR mutation 14% 8% .32b
% ALK rearrangement 2% 0% .16b
% KRAS mutation 57% 43% .22b
% Upfront Steroids 23% 17% .39b
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Figure 1.  Upfront steroids decrease the efficacy of immune checkpoint inhibitors in NSCLCBM. (a) Overall 
Survival differences between those treated with or without upfront steroids. (b) Multivariable analysis of overall 
survival. (c) Progression-free survival differences between those treated with or without upfront steroids. (d) 
Multivariable analysis of progression-free survival. (a) and (c) group differences tested with the Wilcoxon test. 
(b) and (d) estimates from Cox proportional hazards models and the associations tested with effect likelihood 
ratio tests.
Figure 2.  NLR is associated with overall survival after start of ICI but not associated with PFS. (a) Overall 
Survival differences between those with NLR ≥ 5 versus < 5. (b) Multivariable analysis of overall survival. (c) 
Progression-free survival differences between those with NLR ≥ 5 versus < 5. (d) Multivariable analysis of 
progression-free survival. (a) and (c) group differences tested with the Wilcoxon test. (b) and (d) estimates from 
Cox proportional hazards models and the associations tested with effect likelihood ratio tests.
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Upfront steroids. Our study aimed to investigate the impact of steroids and NLR in NSCLCBM patients. In 
concordance with the literature, our study showed that the use of upfront steroids was associated with reduced 
OS and PFS in NSCLCBM treated with  ICI11–14. Arbour et al.13 reported that upfront use of steroids (> 10 mg of 
prednisone) was associated with decreased OS in patients with NSCLC. However, Ricciuti et al.15 showed that 
the negative impact of steroids was only seen in patients who received steroids for cancer-related palliation, 
suggesting that the observed difference may be driven by the poor prognosis of the steroid subgroup and not 
diminished efficacy of  ICI15. Our study furthers this work by investigating the impact of steroids in a group of 
NSCLCBM patients who are likely to have a poor prognosis. Using this methodology, we found that steroids do 
impact the intracranial progression of disease and OS.
Table 2.  Multivariable analysis of OS including upfront steroids, NLR and an interaction term between 
upfront steroids and NLR. Estimates from Cox proportional hazards models and the associations tested with 
effect likelihood ratio tests.
Hazard ratio p value
Age 1.03 .05
Number of Baseline Intracranial Lesions 1.05 .14
Neurologic Symptoms 1.01 .96
KPS 1.00 .79
Extra-cranial Metastases 1.29 .26
Steroid – .08
NLR – .40
Interaction term (Steroid X NLR) – .0008
Figure 3.  Association of upfront steroids with OS is dependent on NLR. (a) A model was generated utilizing 
known predictors of OS in NSCLCBM, upfront steroid use, NLR as well as an interaction term between NLR 
and upfront steroids. The hazard ratio of upfront steroid use was calculated at varying NLRs. Impact of upfront 
steroids was then analyzed based on NLR less than 4 (b) and NLR greater than or equal to 4 (c).
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Neutrophil to lymphocyte ratio. Our results demonstrated a strong association between OS and NLR 
across multiple cut-offs, as previously reported in patients with NSCLC treated with  ICI21–24. However, associa-
tion between OS and NLR in patients with NSCLC is independent of  ICI31. A recent meta-analysis (n = 27 arti-
cles) reported a correlation between OS and NLR in NSCLC patients treated with chemotherapy, bevacizumab, 
immunotherapy, and targeted  therapies32–35. Additionally NLR levels correlate with survival in NSCLCBM 
patients treated with  SRS36, or undergoing  surgery37. Our study adds to the literature by demonstrating that 
while NLR is a strong predictor of OS, there is little evidence that NLR predicts the intracranial response to ICI. 
Intracranial PFS is a measure of therapeutic response and contrary to our hypothesis, the absence of difference 
in PFS suggests NLR does not directly impact the efficacy of ICI. Based on our intracranial finding and the fact 
that NLR correlates with OS across treatments in NSCLC, we propose that NLR should be understood as a 
prognostic factor, much like graded prognostic assessment, and not a measure specific to immune activation.
Interaction between steroids and neutrophil to lymphocyte ratio. We investigated interaction 
between baseline NLR and upfront steroid use to determine whether NLR could predict the impact of steroids 
on ICI efficacy. Our data suggests that there is a range of NLR values, below 4 where steroid use impacts the 
efficacy of ICI, likely through the suppression of the immune response. However, as NLR increases, steroids no 
longer diminish the efficacy of ICI. This may be attributed to the fact that the prognosis in these patients is so 
poor that ICI is likely minimally effective. Our data suggest that in healthier patients (lower NLR), upfront ster-
oids appear to significantly diminish the efficacy of ICI.
Local therapy. The relationship between ICI and radiotherapy has been demonstrated to be  important11. 
We found that patients receiving WBRT with ICI had a poor prognosis. We hypothesize that this is highlight-
ing a population of patients receiving palliative WBRT compared to those receiving SRS but the study was not 
designed to investigate this further. Additionally, we investigated the impact of SRS our outcome and found no 
significant results, which is likely a function of only 11 patients not receiving SRS.
Strengths and limitations. The retrospective nature of this project comes with its inherent limitations, 
such as selection, treatment, and elimination bias. Within our study, patients were not randomized, NLR was 
not available for all patients and the collection of KPS and neurologic symptoms relied on documentation in the 
electronic medical record. The patients received five different ICI therapies. We investigated the importance of 
type of ICI and saw no correlation with or impact on any of our result, however, there remains a possibility each 
drug behaves differently. Finally, NLR is a crude marker of inflammation and more complex models of inflam-
matory status have been developed that integrate a wide range of cytokines and may provide a clearer picture. 
Nevertheless, our study provides insight into the interaction between steroids, NLR, and clinical outcomes in a 
large cohort of patients at a tertiary care multidisciplinary NeuroOncology center.
Conclusion
NLR is associated with OS in patients with NSCLCBM treated with ICI, but demonstrated no association with 
PFS. In patients with low NLR, upfront steroid treatment decreases the efficacy of ICI. Our data suggests that 
when clinicians are balancing improving a patients quality of life with steroids and their fear of diminishing 
the efficacy of ICI, NLR is an objective and widely available clinical marker that can be utilized to determine in 
which patients steroids may be detrimental to OS. This research needs further prospective validation in a larger 
randomized controlled study.
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